By Fineline Cube Yiling Pharmaceutical (SHE: 002603) announced that it has submitted an Investigational New Drug (IND) application in China for LB220‑D08, its independently developed small‑molecule candidate for the treatment of atypical hemolytic uremic syndrome (aHUS). The filing marks the company’s entry into the complement‑mediated rare disease space.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | China NMPA |
| Submission Type | IND application |
| Product | LB220‑D08 (Class 1 innovative chemical drug) |
| Indication | Atypical hemolytic uremic syndrome (aHUS) |
| Announcement Date | 13 Aug 2026 |
| Next Steps | IND review clearance; initiation of clinical development in China |
Drug Profile & Mechanism of Action
- Molecule: LB220‑D08, an innovative novel small‑molecule chemical drug, designated a Class 1 innovative chemical drug with proprietary intellectual property rights, independently developed by Yiling Pharmaceutical
- Target: Selectively targets Factor B, a key component of the alternative complement pathway
- Mechanism: Inhibits the alternative complement pathway and blocks activation of C3 convertase, preventing the generation of toxins C3a and C5a and the formation of C5 convertase and the membrane attack complex (MAC, C5b‑9)
- Selectivity Advantage: Preserves normal physiological functions of the lectin and classical complement pathways, potentially offering a more targeted safety profile versus broader complement inhibition
Disease Background – aHUS
| Element | Detail |
|---|---|
| Disease | Atypical hemolytic uremic syndrome (aHUS) |
| Nature | Rare, life‑threatening complement‑mediated thrombotic microangiopathy |
| Pathophysiology | Uncontrolled activation of the alternative complement pathway drives thrombosis, hemolysis, and organ damage, particularly in the kidneys |
| Unmet Need | High cost of existing complement‑targeted biologics and lifelong treatment burden leave room for differentiated oral alternatives |
Market Impact & Outlook
- Rare Disease Opportunity: aHUS is a rare but severe complement‑mediated disorder with limited treatment options; a targeted small‑molecule approach could address significant unmet need.
- Mechanism Differentiation: By selectively inhibiting Factor B while sparing the lectin and classical pathways, LB220‑D08 is designed to suppress disease‑driving complement activity without broad immunosuppression — a profile that, if validated clinically, could differentiate it from existing C5‑targeting antibodies.
- Portfolio Diversification: The IND filing extends Yiling Pharmaceutical’s pipeline beyond its established franchises into innovative chemical drugs and complement‑mediated rare diseases.
- Strategic Positioning: With proprietary intellectual property and Class 1 designation, the program positions Yiling to compete in the fast‑evolving Factor B inhibitor landscape, where global interest in oral complement therapies continues to grow.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory review, clinical development, and commercial potential for LB220‑D08. Actual results may differ due to risks including IND clearance outcomes, clinical trial results, and competitive dynamics in the complement inhibitor market.-Fineline Info & Tech